Report cover image

Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 195 Pages
SKU # APRC20359365

Description

Summary

According to APO Research, the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market include Allergan, Amneal Pharms, Astellas Pharmaceuticals, Bausch Health, Sebela Pharmaceuticals and Pharscin Pharma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs sales, projected growth trends, production technology, application and end-user industry.

Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Company

Allergan
Amneal Pharms
Astellas Pharmaceuticals
Bausch Health
Sebela Pharmaceuticals
Pharscin Pharma
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Type

XIFAXAN
Lotronex
Viberzi
Other
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Application

Hospitals Pharmacy
Retail Pharmacy
Other
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs significant trends, drivers, influence factors in global and regions.
6. To analyze Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs industry.
Chapter 3: Detailed analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Table of Contents

195 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value (2020-2031)
1.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume (2020-2031)
1.2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Dynamics
2.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Trends
2.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Drivers
2.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Opportunities and Challenges
2.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Restraints
3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by Company
3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Company Revenue Ranking in 2024
3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Company (2020-2025)
3.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Company (2020-2025)
3.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price by Company (2020-2025)
3.5 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Company Ranking (2023-2025)
3.6 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Company Manufacturing Base and Headquarters
3.7 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Company Product Type and Application
3.8 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by Type
4.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Type Introduction
4.1.1 XIFAXAN
4.1.2 Lotronex
4.1.3 Viberzi
4.1.4 Other
4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Type
4.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Type (2020-2031)
4.2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume Share by Type (2020-2031)
4.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Type
4.3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Type (2020-2031)
4.3.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type (2020-2031)
5 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by Application
5.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Application Introduction
5.1.1 Hospitals Pharmacy
5.1.2 Retail Pharmacy
5.1.3 Other
5.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Application
5.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Application (2020-2031)
5.2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume Share by Application (2020-2031)
5.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Application
5.3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Application (2020-2031)
5.3.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application (2020-2031)
6 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Regional Sales and Value Analysis
6.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2020-2031)
6.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region: 2020-2025
6.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2026-2031)
6.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Region (2020-2031)
6.4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Region: 2020-2025
6.4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Region (2026-2031)
6.5 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value (2020-2031)
6.6.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value (2020-2031)
6.7.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value (2020-2031)
6.8.2 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value (2020-2031)
6.9.2 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value (2020-2031)
6.10.2 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Country, 2024 VS 2031
7 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Country-level Sales and Value Analysis
7.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2020-2031)
7.3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2020-2025)
7.3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2026-2031)
7.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Country (2020-2031)
7.4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Country (2020-2025)
7.4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2020-2031)
7.5.2 USA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2020-2031)
7.6.2 Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2020-2031)
7.8.2 Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2020-2031)
7.9.2 France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2024 VS 2031
7.9.3 France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2020-2031)
7.11.2 Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2020-2031)
7.12.2 Spain Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2020-2031)
7.13.2 Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2020-2031)
7.16.2 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2024 VS 2031
7.16.3 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2020-2031)
7.17.2 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2020-2031)
7.19.2 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2024 VS 2031
7.19.3 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2020-2031)
7.20.2 Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2020-2031)
7.24.2 Chile Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2020-2031)
7.26.2 Peru Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2020-2031)
7.28.2 Israel Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2020-2031)
7.29.2 UAE Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2020-2031)
7.31.2 Iran Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Allergan
8.1.1 Allergan Comapny Information
8.1.2 Allergan Business Overview
8.1.3 Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Value and Gross Margin (2020-2025)
8.1.4 Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
8.1.5 Allergan Recent Developments
8.2 Amneal Pharms
8.2.1 Amneal Pharms Comapny Information
8.2.2 Amneal Pharms Business Overview
8.2.3 Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Value and Gross Margin (2020-2025)
8.2.4 Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
8.2.5 Amneal Pharms Recent Developments
8.3 Astellas Pharmaceuticals
8.3.1 Astellas Pharmaceuticals Comapny Information
8.3.2 Astellas Pharmaceuticals Business Overview
8.3.3 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Value and Gross Margin (2020-2025)
8.3.4 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
8.3.5 Astellas Pharmaceuticals Recent Developments
8.4 Bausch Health
8.4.1 Bausch Health Comapny Information
8.4.2 Bausch Health Business Overview
8.4.3 Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Value and Gross Margin (2020-2025)
8.4.4 Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
8.4.5 Bausch Health Recent Developments
8.5 Sebela Pharmaceuticals
8.5.1 Sebela Pharmaceuticals Comapny Information
8.5.2 Sebela Pharmaceuticals Business Overview
8.5.3 Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Value and Gross Margin (2020-2025)
8.5.4 Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
8.5.5 Sebela Pharmaceuticals Recent Developments
8.6 Pharscin Pharma
8.6.1 Pharscin Pharma Comapny Information
8.6.2 Pharscin Pharma Business Overview
8.6.3 Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Value and Gross Margin (2020-2025)
8.6.4 Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
8.6.5 Pharscin Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Chain Analysis
9.1.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Mode & Process
9.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors
9.2.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.